Search results
Results From The WOW.Com Content Network
COVID-19 pandemic. IndoVac is a recombinant protein subunit COVID-19 vaccine, [1][2] developed by Indonesian pharmaceutical company Bio Farma and Baylor College of Medicine in Houston, Texas. [1][2] It is the world's first officially halal certified COVID-19 vaccine, [3] but the most popular existing vaccines had already been widely endorsed as ...
How COVID‑19 vaccines work. The video shows the process of vaccination, from injection with RNA or viral vector vaccines, to uptake and translation, and on to immune system stimulation and effect. Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths ...
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria[6]and Covishield,[7]is a viral vector vaccine[8]produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8][9][10]Finland, Denmark, and Norway suspended the use of the Oxford ...
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. [1] In terms of total doses given, Indonesia ranks third in Asia and fifth in the world. [2]
The Oxford–AstraZeneca COVID‑19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus in order to prevent COVID-19 in adults aged 18 years and older. [ 1 ] The medicine is administered by two 0.5 ml (0.017 US fl oz) doses given by intramuscular injection into the deltoid muscle (upper arm).
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, [1] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. [31] It contains a recombinant spike protein from the SARS-CoV-2 Omicron variant lineage JN.1.
v. t. e. AD5-nCOV, trade-named Convidecia, is a single-dose [1] viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics, with Phase III trials conducted in Argentina, [2] Chile, [3] Mexico, [4] Pakistan, [5] Russia, [6] and Saudi Arabia [7] with 40,000 participants.
e. AWcorna, originally termed ARCoV [2] and also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science. [3] In contrast to other mRNA COVID vaccines, such as those by Pfizer-BioNtech and Moderna, this vaccine primarily targets the ...